Pharmaceutical - Financial, Licensing


Current filters:


Popular Filters

1 to 25 of 78 results

Glenmark gets $4 million milestone in Forest collaboration

Glenmark gets $4 million milestone in Forest collaboration


Indian drugmaker Glenmark Pharmaceuticals has informed the Stock Exchange today that the company through…

FinancialForest LaboratoriesGlenmark PharmaceuticalsInflammatory diseasesLicensingPharmaceutical

Merck returns rights to ridaforolimus to Ariad, whose 4th-qtr net loss widens

Merck returns rights to ridaforolimus to Ariad, whose 4th-qtr net loss widens


US pharma giant Merck & Co has told partner Ariad Pharmaceutical that it is terminating its license agreement…

Ariad PharmaceuticalsFinancialLicensingMerck & CoOncologyPharmaceuticalridaforolimus

$20 million milestones for MacroGenics from Servier

$20 million milestones for MacroGenics from Servier


Servier, France’s largest privately‐held pharmaceutical company, has exercised its exclusive option…


Forest spends $240 million for US rights to Saphris; streamlines operations


US drugmaker Forest Laboratories is acquiring exclusive rights in the USA for Saphris (asenapine) sublingual…

FinancialForest LaboratoriesLicensingMerck & CoNeurologicalNorth AmericaPharmaceuticalSaphrisUSA

Baxter buys exclusive rights to CTI’s cancer drug pacritinib


USA-based companies Baxter International and Cell Therapeutics have entered into an exclusive worldwide…

Baxter InternationalCell TherapeuticsFinancialGlobalLicensingOncologypacritinibPharmaceutical

Immunocore makes progress in deal with GSK

Immunocore makes progress in deal with GSK


UK-based biotech firm Immunocore has achieved its first milestone in its major research and licensing…


PDL BioPharma secures royalties on diabetes products in $240m deal

PDL BioPharma secures royalties on diabetes products in $240m deal


PDL BioPharma has acquired the rights to receive royalties and milestones payable on sales of Type 2…

DepomedDiabetesFinancialGlumetzaInvokanaJanumetLicensingmetforminNorth AmericaPDL BioPharmaPharmaceutical

Astellas links with Mitokyne on mitochondria-related therapies

Astellas links with Mitokyne on mitochondria-related therapies


Japanese drug major Astellas Pharma and USA-based start-up Mitokyne have entered into an exclusive R&D…

Astellas PharmaFinancialLicensingMergers & AcquisitionsMitokynePharmaceuticalResearch

Isis earns milestone payments from GlaxoSmithKline

Isis earns milestone payments from GlaxoSmithKline


US biotech firm Isis Pharmaceuticals says that UK pharma giant GlaxoSmithKline has added a development…

BiotechnologyFinancialGlaxoSmithKlineIsis PharmaceuticalsLicensingPharmaceuticalRare diseases

First-half 2013 sees fall in licensing, says Evaluate


Despite a positive start to the year characterized by healthy initial public offering (IPO) activity…

FinancialLicensingMergers & AcquisitionsPharmaceutical

DRI Capital raises $1.45 billion for Drug Royalty III


DRI Capital, a global leader in the acquisition of health care royalties, today (September 9) announced…


Karo Bio gets first milestone in Pfizer collaboration


Under its collaboration with US pharma behemoth Pfizer (NYSE: PFE), Sweden's Karo Bio (STO: KARO) says…

Anti-Arthritics/RheumaticsDermatologicalsFinancialKaro BioLicensingNeurologicalPfizerPharmaceuticalResearch

Repligen gets first milestone under SMA deal with Pfizer


USA-based Repligen (Nasdaq: RGEN) says it has received a $1 million milestone payment from global drugs…

FinancialLicensingPfizerPharmaceuticalRare diseasesRepligen

ObsEva gets funding and makes deal with Merck Serono


Geneva, Switzerland-based ObsEva says that it has closed a 32 million Swiss franc ($34.8 million) -A…

FinancialLicensingMerck KGaAMerck SeronoObsEvaPharmaceuticalWomen's Health

Nektar hedges bets on deal with AstraZeneca


Along with presenting second-quarter financial results, Howard Robin, president and chief executive of…

AstraZenecaFinancialGastro-intestinalsLicensingnaloxegolNektar TherapeuticsPharmaceutical

Quest Diagnostics sells ibrutinib royalty rights for $485 million


USA-based diagnostic services firm Quest Diagnostics (NYSE: DGX) says it has completed the sale of its…

FinancialibrutinibLicensingOncologyPharmaceuticalQuest DiagnosticsRoyalty Pharma

Paladin and Bioniche officially close debt refinancing and Urocidin licensing deals


Canadian companies Bioniche Life Sciences (TSX: BNC) and Paladin Labs (TSX: PLB) said on Friday (July…

Bioniche Life SciencesFinancialLicensingOncologyPaladin LabsPharmaceuticalUrocidin

NeuroVive signs deal with Isomerase Therapeutics; receives the first milestone from Sihuan


Swedish mitochondrial medicine firm NeuroVive Pharmaceutical has signed a collaboration agreement with…

FinancialIsomerase TherapeuticsLicensingNeuroVivePharmaceuticalSihuan Pharmaceutical

Life Sciences IPOs have biggest month - May - in 13 years, reports Burrill


A total of eight life sciences companies went public on US exchanges in May, the busiest month for initial…

BiotechnologyFinancialLicensingMergers & AcquisitionsPharmaceutical

GlaxoSmithKline buys rights to MorphoSys RA drug candidate for up to $577 million


German biotech firm MorphoSys (FSE: MOR) yesterday (June 3) saw its shares leap as much as 6%, as it…


Alexza deal with Teva sets stage for Adasuve, say analysts


USA-based Alexza Pharmaceuticals' (Nasdaq: ALXA) US marketing deal with Israel-headquartered Teva Pharmaceutical…

AdasuveAlexza PharmaceuticalAZ-002FinancialLicensingNeurologicalPharmaceuticalTeva Pharmaceutical Industries

Elan pays $1 billion for a 21% share of Theravance royalties on four respiratory programs


US biotech firm Theravance (Nasdaq: THRX) has entered into a royalty participation agreement wherein…

Anoro ElliptaBiotechnologyBreo ElliptaElanFinancialGlaxoSmithKlineLicensingPharmaceuticalRespiratory and PulmonaryTheravance

Trevena and Forest Labs collaborate on TRV027 for acute heart failure


US GPCR ligand drug developer Trevena and Forest Laboratories (NYSE: FRX) have entered into a collaborative…

Cardio-vascularFinancialForest LaboratoriesLicensingPharmaceuticalTrevenaTRV027

Regeneron acquires rights to two ophthalmology programs from Sanofi


US biotech firm Regeneron Pharmaceuticals (Nasdaq: REGN) has expanded its ophthalmology portfolio by…


1 to 25 of 78 results

Back to top